vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»10.15690/vsp.v13i4.1088vsp-171Research ArticleОБМЕН ОПЫТОМEXCHANGE OF EXPERIENCEНОВЫЕ ЛЕКАРСТВЕННЫЕ ФОРМЫ ГИДРОКОРТИЗОНА 17-БУТИРАТА В АРСЕНАЛЕ СРЕДСТВ ДЛЯ НАРУЖНОЙ ТЕРАПИИ АТОПИЧЕСКОГО ДЕРМАТИТА У ДЕТЕЙNEW FORMULATIONS OF HYDROCORTISONE-17-BUTYRATE IN THE ARSENAL OF MEANS FOR TOPICAL TREATMENT OF ATOPIC DERMATITIS IN CHILDRENКороткийН. Г.KorotkiiN. G.kng40@mail.ruГамаюновБ. Н.GamayunovB. N.

Korotkii Nikolai Gavrilovich, PhD, professor, Head of Dermatovenereological Department of Pediatric Faculty

kng40@mail.ruРоссийский национальный исследовательский медицинский университет им. Н.И. Пирогова, МоскваРоссияPirogov Russian National Research Medical University, MoscowRussian FederationРоссийская детская клиническая больница, МоскваРоссияRussian Child Clinical Hospital, MoscowRussian Federation201402082014134Вопросы современной педиатрии7477Copyright © Короткий Н.Г., Гамаюнов Б.Н., 20142014Короткий Н.Г., Гамаюнов Б.Н.Korotkii N.G., Gamayunov B.N.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/171

Наружная терапия атопического дерматита у детей остается сложной и многофакторной проблемой. Нерациональный выбор средств лечения может повлечь ухудшение состояния ребенка, вызывать осложнения дерматоза, способствовать развитию «атопического марша». «Золотым стандартом» наружной терапии атопического дерматита остаются топические глюкокортикоиды. Их применение не ограничивается традиционными лекарственными формами, такими как крем и мазь. Представлены особенности новых лекарственных форм (эмульсии с разным содержанием липидов), сформулированы рекомендации по их практическому использованию, описан клинический опыт их использования при лечении детей с атопическим дерматитом.

Topical therapy of atopic dermatitis in children is a complex and multifactorial problem. Irrational choice of means of treatment may lead to the deterioration of the child, cause complications of dermatosis, promote the development of «atopic march». Topical treatment’s «Gold standard» is topical corticosteroids. The application of these medicines is not limited to conventional dosage forms such as cream and ointment. The features of the new formulations are presented (emulsions with different lipid concentration), the recommendations on their practical use are stated, the clinical experience of their application in the treatment of children with atopic dermatitis is described.

детиатопический дерматитлечениетопические глюкокортикоидыгидрокортизона 17-бутиратchildrenatopic dermatitistreatmenttopical corticosteroidshydrocortisone-17-butyrateКомпания «Астеллас»“Astellas”ReferencesHandbook of Atopic Eczema. 2nd edn. Ring J.B. Przybilla, T. Ruzicka (eds.). Heidelberg: Springer. 2006.Handbook of Atopic Eczema. 2nd edn. Ring J.B. Przybilla, T. Ruzicka (eds.). Heidelberg: Springer. 2006.Ring J. Allergy in Practice. Heidelberg: Springer. 2004. 635 p.Ring J. Allergy in Practice. Heidelberg: Springer. 2004. 635 p.Johansson S.G., Bieber T., Dahl R., Friedmann P.S., Lanier B.Q., Lockey R.F. et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J. Allergy Clin. Immunol. 2004; 113: 832–836.Johansson S.G., Bieber T., Dahl R., Friedmann P.S., Lanier B.Q., Lockey R.F. et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J. Allergy Clin. Immunol. 2004; 113: 832–836.Khaitov R. M., Kubanova A. A. Consilium medicum — Consilium medicum. 2004; 3: 167–173.Khaitov R. M., Kubanova A. A. Consilium medicum — Consilium medicum. 2004; 3: 167–173.Carrol C.L., Balkrishnan R., Feldman S.R., Fleisher A.B., Jr, Manuel J.C. The burden of atopic dermatitis: impact on the patient, family and society. Pediatr. Dermatol. 2005; 22: 192–199.Carrol C.L., Balkrishnan R., Feldman S.R., Fleisher A.B., Jr, Manuel J.C. The burden of atopic dermatitis: impact on the patient, family and society. Pediatr. Dermatol. 2005; 22: 192–199.Turner J.D., Schwartz R.A. Atopic dermatitis. A clinical challenge. Acta Dermatovenerol. Alp. Panonica Adriat. 2006; 15 (2): 59–68.Turner J.D., Schwartz R.A. Atopic dermatitis. A clinical challenge. Acta Dermatovenerol. Alp. Panonica Adriat. 2006; 15 (2): 59–68.Ong P.Y., Leung D.Y. Immune dysregulation in atopic dermatitis. Curr. Allergy Asthma Rep. 2006; 6 (5): 384–389.Ong P.Y., Leung D.Y. Immune dysregulation in atopic dermatitis. Curr. Allergy Asthma Rep. 2006; 6 (5): 384–389.Leung D.Y. Our evolving understanding of the functional role of filaggrin in atopic dermatitis. J. Allergy Clin. Immunol. 2009; 124 (3): 494–495.Leung D.Y. Our evolving understanding of the functional role of filaggrin in atopic dermatitis. J. Allergy Clin. Immunol. 2009; 124 (3): 494–495.Korotkii N. G., Tikhomirov A. A., Gamayunov B. N. Klin. dermatol. i venerol. — Clinical dermatology and venereology. 2013; 4: 51–55.Korotkii N. G., Tikhomirov A. A., Gamayunov B. N. Klin. dermatol. i venerol. — Clinical dermatology and venereology. 2013; 4: 51–55.Baumer J.H. Guideline review: atopic eczema in children. Arch. Dis. Child. Edu. Pract. Ed. 2008; 93 (3): 93–97.Baumer J.H. Guideline review: atopic eczema in children. Arch. Dis. Child. Edu. Pract. Ed. 2008; 93 (3): 93–97.Korotkii N. G., Tikhomirov A. A., Andreenko O. N., Gamayunov B. N. Opyt primeneniya mazi lokoid v terapii detei s khronicheskimi vospalitel’nymi zabolevaniyami kozhi. Sb. trudov yubileinoi nauch.-prakt. konf. «Aktual’nye voprosy i osobennosti dermatovenerologii v detskom vozraste. Problemy i perspektivy» [Experience in the Application of the Ointment Lokoid in Therapy of Children with Chronic Inflammatory Diseases of the Skin. Proceedings of the Anniversary Scientific-Practical. Conf. “Actual Issues and Features of Dermatovenereology in Childhood. Problems and Prospects”]. Moscow, Meditsinskaya kniga, 2007. pp. 91–94.Korotkii N. G., Tikhomirov A. A., Andreenko O. N., Gamayunov B. N. Opyt primeneniya mazi lokoid v terapii detei s khronicheskimi vospalitel’nymi zabolevaniyami kozhi. Sb. trudov yubileinoi nauch.-prakt. konf. «Aktual’nye voprosy i osobennosti dermatovenerologii v detskom vozraste. Problemy i perspektivy» [Experience in the Application of the Ointment Lokoid in Therapy of Children with Chronic Inflammatory Diseases of the Skin. Proceedings of the Anniversary Scientific-Practical. Conf. “Actual Issues and Features of Dermatovenereology in Childhood. Problems and Prospects”]. Moscow, Meditsinskaya kniga, 2007. pp. 91–94.Schafer-Korting M., Kleuser B., Ahmed M., Holtje H.D., Korting H.C. Glucocorticoids for human skin: new aspects of the mechanism of action. Skin Pharmacol. Physiol. 2005; 18: 103–114.Schafer-Korting M., Kleuser B., Ahmed M., Holtje H.D., Korting H.C. Glucocorticoids for human skin: new aspects of the mechanism of action. Skin Pharmacol. Physiol. 2005; 18: 103–114.Brazzini B., Pimpinelli N. New and established topical corticosteroids in dermatology: clinical pharmacology and therapeutic use. Am. J. Clin. Dermatol. 2002; 3 (1): 47–58.Brazzini B., Pimpinelli N. New and established topical corticosteroids in dermatology: clinical pharmacology and therapeutic use. Am. J. Clin. Dermatol. 2002; 3 (1): 47–58.Tadicherla S., Ross K, Shenefelt P.D., Fenske N.A. Topical corticosteroids in dermatology. J. Drugs Dermatol. 2009; 8 (12): 1093–1105.Tadicherla S., Ross K, Shenefelt P.D., Fenske N.A. Topical corticosteroids in dermatology. J. Drugs Dermatol. 2009; 8 (12): 1093–1105.Pierard GE. Hydrocortisone 17-butyrate (Locoid). A thirtyyear ongoing innovative drug. Rev. Med. Liege. 2006; 61 (2): 128–130.Pierard GE. Hydrocortisone 17-butyrate (Locoid). A thirtyyear ongoing innovative drug. Rev. Med. Liege. 2006; 61 (2): 128–130.Wieriks J., Hespe W., Jaitly K.D., van Kan B.L. Topical and systemic effects of hydrocortisone 17-butyrate. Dermatologica. 1976; 152 (Suppl. 1): 181–195.Wieriks J., Hespe W., Jaitly K.D., van Kan B.L. Topical and systemic effects of hydrocortisone 17-butyrate. Dermatologica. 1976; 152 (Suppl. 1): 181–195.Kochergin N. G., Petrunin D. D. Klin. dermatol. i venerol. — Clinical dermatology and venereology. 2011; 6: 84–94.Kochergin N. G., Petrunin D. D. Klin. dermatol. i venerol. — Clinical dermatology and venereology. 2011; 6: 84–94.

The authors declare that there are no conflicts of interest present.